Aripiprazole Tablet
Product Images NDC 65862-666

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 65862-666). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: The Effects Of Other Drugs On Aripiprazole Pharmacokinetics (Aripiprazole Fig1)

A forest plot chart titled 'The effects of other drugs on aripiprazole pharmacokinetics' displaying fold changes and 90% confidence intervals for aripiprazole's AUC and Cmax values when co-administered with various interacting drugs such as CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lorazepam). The x-axis shows change relative to reference without interacting drug, ranging approximately from 0.5 to 3.0.*

FDA Label Image

Package Label-principal Display Panel (5 mg Blister Carton (10 x 10) Unit-dose Tablets)

Label for Aripiprazole Tablets USP 5 mg, a tablet dosage form supplied in a package of 30 tablets. The label includes dosage strength, storage instructions, pharmacological guidance to dispense the medication guide, distributor details (Aurobindo Pharma USA, Inc.), and manufacturing origin (India). The label also shows an NDC code and barcode, with a designated coding area for printing.*

FDA Label Image

Package Label-principal Display Panel (10 mg (30 Tablets Bottle))

Packaging label for Aripiprazole Tablets USP 5 mg by Aurobindo Pharma Limited. The label indicates a package containing 100 unit-dose tablets (10 x 10). It includes a note for pharmacists to dispense the medication guide separately. The label features barcodes, NDC 65862-662-78, and manufacturer details noting the product is made in India and distributed by Aurobindo Pharma USA, Inc.*

FDA Label Image

Package Label-principal Display Panel (10 mg Blister Carton (10 x 10) Unit-dose Tablets)

Label for Aripiprazole Tablets USP 10 mg by Aurobindo Pharma Limited. The label indicates a package containing 30 tablets. It includes dosage form, strength, storage instructions, distributor information (Aurobindo Pharma USA, Inc.), and a barcode. The label features instructions to dispense the Medication Guide separately and notes that the tablets contain Aripiprazole USP 10 mg.*

FDA Label Image

Package Label-principal Display Panel (15 mg (30 Tablets Bottle))

Packaging label for Aripiprazole Tablets USP 10 mg by Aurobindo Pharma Limited. The label indicates a count of 100 unit-dose tablets (10 x 10) and includes the NDC 65862-663-78. The text advises pharmacists to dispense the medication guide separately to each patient. The label features the product name, strength, and manufacturer logo with design elements in green, blue, and magenta.*

FDA Label Image

Package Label-principal Display Panel (15 mg Blister Carton (10 x 10) Unit-dose Tablets)

Label for Aripiprazole Tablets USP 15 mg, a tablet product by Aurobindo Pharma Limited. The label indicates the package contains 30 tablets and includes storage instructions between 20° to 25°C. It also notes dispensing pharmacist guidelines, distributor information for Aurobindo Pharma USA, and a coding area for printing on the label.*

FDA Label Image

Package Label-principal Display Panel (20 mg (30 Tablets Bottle))

Packaging label for Aripiprazole Tablets USP 15 mg manufactured by Aurobindo Pharma Limited. The label indicates the product is Rx only and comes in unit-dose tablets with a total count of 100 (10 x 10) tablets. The NDC number is 65862-664-78. The label reminds pharmacists to dispense a separate Medication Guide to each patient.*

FDA Label Image

Package Label-principal Display Panel (20 mg Blister Carton (10 x 10) Unit-dose Tablets)

Label for Aripiprazole Tablets USP 20 mg, a drug tablet product by Aurobindo Pharma Limited. The label states each tablet contains Aripiprazole USP 20 mg and comes in a bottle of 30 tablets. It includes storage instructions, distributor information for Aurobindo Pharma USA, Inc., and a barcode on the right side.*

FDA Label Image

Package Label-principal Display Panel (30 mg (30 Tablets Bottle))

Packaging label for Aripiprazole Tablets USP 20 mg, a tablet dosage form by Aurobindo Pharma Limited. The label indicates a package containing 100 unit-dose tablets (10 x 10). The label includes prescribing status as Rx only and instructions for pharmacists to dispense medication guides separately.*

FDA Label Image

Package Label-principal Display Panel (30 mg Blister Carton (10 x 10) Unit-dose Tablets)

Label for Aripiprazole Tablets USP 30 mg by Aurobindo Pharma Limited. The label indicates the product contains 30 mg Aripiprazole per tablet, with a total quantity of 30 tablets. It includes storage instructions, distributor information for Aurobindo Pharma USA, Inc., and a noted coding area for printing over the label.*

FDA Label Image

Aripiprazole Fig19

Packaging label for Aripiprazole Tablets USP 30 mg manufactured by Aurobindo Pharma Limited. The label displays the product name, strength (30 mg), the dosage form as unit-dose tablets, and a count of 100 (10 x 10) tablets. It includes the NDC number 65862-666-78 and instructions for the pharmacist to dispense the medication guide separately. The design features a blue and green color scheme with the Aurobindo logo.*

FDA Label Image

Figure 2: The Effects Of Other Drugs On Dehydro-aripiprazole Pharmacokinetics (Aripiprazole Fig2)

A scatter plot graph showing the effects of various drugs on dehydro-aripiprazole pharmacokinetics. The horizontal axis represents fold change relative to reference without interacting drug, ranging from 0.0 to 3.0. The vertical axis lists drugs categorized as CYP3A4 inhibitor, CYP2D6 inhibitor, CYP3A4 inducer, gastric acid blockers, and others. Data points illustrate fold changes in AUC and Cmax with 90% confidence intervals for each drug, including ketoconazole, quinidine, carbamazepine, famotidine, valproate, and lorazepam.*

FDA Label Image

Figure3: The Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig3)

A pharmacokinetic chart depicting the effects of aripiprazole on the pharmacokinetics of various other drugs. It shows fold changes with 90% confidence intervals in parameters such as AUC, Cmax, and INR for drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lorazepam, and venlafaxine relative to reference without interacting drug.*

FDA Label Image

Figure4: Effects Of Intrinsic Factors On Aripiprazole Pharmacokinetics (Aripiprazole Fig4)

A chart depicting Aripiprazole fold change and 90% confidence intervals for various special populations, including CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The x-axis shows change relative to reference, and the y-axis compares AUC and Cmax values across these groups.*

FDA Label Image

Figure 5: Effects Of Intrinsic Factors On Dehydro-aripiprazole Pharmacokinetics (Aripiprazole Fig5)

A pharmacokinetic chart illustrating the effects of intrinsic factors on dehydro-aripiprazole, showing fold change and 90% confidence intervals for parameters AUC and Cmax. Factors compared include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with changes plotted relative to a reference value.*

FDA Label Image

Figure 6: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (schizophrenia Study 5) (Aripiprazole Fig6)

A Kaplan-Meier estimation curve showing the cumulative proportion of patients with relapse over time in a schizophrenia study. The graph compares Aripiprazole and placebo groups across days from randomization, with Aripiprazole showing a lower proportion of relapse compared to placebo. The number of subjects at risk is displayed below the time axis for both groups.*

FDA Label Image

Package Label-principal Display Panel (2 mg (30 Tablets Bottle))

A line graph showing the change in YGTSS total TIC score from baseline over eight weeks of treatment. The graph compares three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo. The vertical axis represents the least-squares mean change in YGTSS total TIC score, while the horizontal axis represents weeks of treatment from 0 to 8. Both Aripiprazole groups show a greater reduction in TIC scores over time compared to placebo.*

FDA Label Image

Package Label-principal Display Panel (2 mg Blister Carton (10 x 10) Unit-dose Tablets)

Aripiprazole Tablets USP 2 mg label by Aurobindo Pharma Limited. The label indicates prescription use and dosage form as tablets. It contains 30 tablets per package and notes storage instructions at controlled room temperature. The label also includes distributor information and barcode.*

FDA Label Image

Package Label-principal Display Panel (5 mg (30 Tablets Bottle))

Packaging label for Aripiprazole Tablets USP 2 mg by Aurobindo Pharma Limited. The label indicates this is a prescription medication with 100 unit-dose tablets (10 x 10) per package. The label includes NDC 65862-661-78 and highlights the 2 mg strength prominently on multiple panels.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Str)

Chemical structure of Aripiprazole, showing its molecular framework including chlorophenyl, piperazine, and quinolinone moieties connected via an ether-linked aliphatic chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.